10x Genomics (TXG) EBIT (2018 - 2026)

10x Genomics has disclosed EBIT across 9 years of filings, most recently posting -$19.6 million for Q2 2026.

• In Q2 2026, EBIT fell 164.91% year-over-year to -$19.6 million; the TTM figure through Jun 2026 stood at -$88.4 million (up 12.08% YoY), while the FY2025 annual figure was -$61.0 million, up 68.65% from the prior year.
• EBIT came in at -$19.6 million for Q2 2026 at 10x Genomics, down from -$17.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $30.1 million in Q2 2025 to a low of -$94.8 million in Q3 2023.
• Average EBIT over 5 years is -$40.3 million, with a median of -$41.6 million recorded in 2022.
• Year-over-year, EBIT plunged 511.13% in 2022 and soared 172.18% in 2025.
• Over 5 years, EBIT stood at -$23.1 million in 2022, then plunged by 138.95% to -$55.2 million in 2023, then increased by 9.69% to -$49.8 million in 2024, then soared by 60.79% to -$19.5 million in 2025, then retreated by 0.07% to -$19.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$19.6 million in Q2 2026, -$17.0 million in Q1 2026, and -$19.5 million in Q4 2025.